CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2008-04-14): CORRECTION: Mortality higher in HCV patients without other significant morbidities

Epidemiology

CORRECTION: Mortality higher in HCV patients without other significant morbidities

Last Updated: 2008-04-14 11:48:24 -0400 (Reuters Health)

[Corrects story posted April 10, 2008. Title has been corrected to HCV from HIV+.]

NEW YORK (Reuters Health) - All-cause, liver, and cardiac mortality is higher among hepatitis C virus (HCV)-seropositive individuals, without other significant comorbidities, compared with HCV-negative individuals. However, most HCV-positive, but otherwise healthy individuals, don't die of liver disease.

"Chronic HCV infection is neither a death sentence nor benign," Dr. Edward L. Murphy from University of California, San Francisco, told Reuters Health. "There is a very strong link to liver disease, but these account for only a minority of deaths among HCV infected persons. More attention needs to be paid to lifestyle and risk behaviors."

Dr. Murphy and colleagues investigated mortality rates among apparently healthy blood donors screened for HCV antibodies at the time of blood donation. Their findings appear in the March 15th issue of the American Journal of Epidemiology.

Overall mortality among HCV-positive donors was 3.13 times higher than that among matched HCV-negative donors, the authors report. HCV seropositivity was also strongly associated with drug/alcohol-related deaths, infectious deaths, liver-related deaths and less strongly with trauma/suicide-related deaths and cardiovascular deaths, the report indicates.

The standardized mortality ratio for the HCV-positive group relative to the US population mortality in 2000 was 2.13, whereas that for the HCV-negative group was 0.71.

"We were somewhat surprised to find an approximately threefold hazard ratio estimate for all-cause mortality," the investigators say. Some studies have suggested that rates of cirrhosis and hepatocellular cancer mortality in HCV-infected subjects have been overestimated.

For example, patients infected through blood transfusions may die from conditions that necessitated transfusion. The researcher had hypothesized that "HCV would not be associated with mortality in an initially healthy blood donor population."

"One message of the paper is that paying attention only to liver status may not be enough," Dr. Murphy said. "The higher rate of cardiovascular mortality suggests paying more attention to cardiovascular risk factors (cholesterol, hypertension, smoking, obesity)."

"In addition, the high rate of mortality related to substance abuse, trauma, and suicide suggests that physicians should screen for and treat substance abuse (including alcohol), psychological disease, and risk-taking behavior."

"We hope that the same kind of analysis can be replicated using other large blood donor databases, such as those maintained by the American Red Cross or in Scandinavia," Dr. Murphy added. "We had trouble getting this article published in our initial target journals: those read by practitioners who treat HCV."

"We wonder if the message of the study is one that some practicing hepatologists, who reviewed our manuscript, found difficult to accept."

Am J Epidemiol 2008;167:743-750.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.